ARTICLE | Clinical News
Halofuginone: Began Phase I/II trial
December 3, 2001 8:00 AM UTC
Collgard Biopharmaceuticals Ltd., Newton, Mass. Product: Halofuginone Business: Cancer Therapeutic category: Angiogenesis Target: MMP-2, Type I collagen transcriptional machinery Description: Small ...